Trial of Immune Globulin in Infant Botulism

Authors

  • J Gordon Millichap Northwestern University Feinberg School of Medicine

DOI:

https://doi.org/10.15844/pedneurbriefs-20-2-5

Keywords:

Human Botulism Immune Globulin Intravenous, Infant Botulism, Werdnig Hoffman

Abstract

A 5-year, randomized, double-blind, placebo-controlled trial of the orphan drug Human Botulism Immune Globulin Intravenous (BIG-IV) in 122 infants in California with confirmed infant botulism (75 caused by type A Clostridium botulinum toxin, and 47 by type B toxin) was conducted at the California Department of Health Services, Richmond, CA; National Botulism Surveillance and Reference Laboratory, CDC and P, Atlanta; and Division of Biostatistics, University of California, Berkeley.

Published

2006-02-01

Issue

Section

Infectious/Autoimmune Disorders